Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 321

1.

Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.

Hostetter C, Licata LA, Witkiewicz A, Costantino CL, Yeo CJ, Brody JR, Keen JC.

Cancer Biol Ther. 2008 Sep;7(9):1496-506. Epub 2008 Sep 23.

PMID:
18769129
2.

Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.

Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Künzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G, Gieschen H, Ulbrich HF, Schneider MR.

J Natl Cancer Inst. 2004 Feb 4;96(3):210-8.

PMID:
14759988
3.

New approaches to the understanding of tamoxifen action and resistance.

Berstein LM, Zheng H, Yue W, Wang JP, Lykkesfeldt AE, Naftolin F, Harada H, Shanabrough M, Santen RJ.

Endocr Relat Cancer. 2003 Jun;10(2):267-77.

PMID:
12790788
4.

An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.

Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B.

Mol Cancer Res. 2008 Oct;6(10):1630-8. doi: 10.1158/1541-7786.MCR-07-2172.

5.

BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.

Brinkman A, van der Flier S, Kok EM, Dorssers LC.

J Natl Cancer Inst. 2000 Jan 19;92(2):112-20.

PMID:
10639512
6.

Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.

Godinho M, Meijer D, Setyono-Han B, Dorssers LC, van Agthoven T.

J Cell Physiol. 2011 Jul;226(7):1741-9. doi: 10.1002/jcp.22503.

PMID:
21506106
7.

Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.

Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL.

Cancer Res. 1999 Nov 1;59(21):5421-4.

8.

Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization.

Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, Gorski SM.

Breast Cancer Res Treat. 2008 Dec;112(3):389-403. doi: 10.1007/s10549-007-9873-4. Epub 2008 Jan 3.

PMID:
18172760
9.

Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.

Chang SB, Miron P, Miron A, Iglehart JD.

J Surg Res. 2007 Mar;138(1):37-44. Epub 2006 Nov 15.

PMID:
17109887
10.

Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells.

Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W.

Steroids. 2009 Jul;74(7):586-94. doi: 10.1016/j.steroids.2008.11.020. Epub 2008 Dec 7. Review.

PMID:
19138696
11.

CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.

Wu M, Soler DR, Abba MC, Nunez MI, Baer R, Hatzis C, Llombart-Cussac A, Llombart-Bosch A, Aldaz CM.

Mol Cancer Res. 2007 Dec;5(12):1285-95. doi: 10.1158/1541-7786.MCR-07-0126.

12.

Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.

Tan S, Ding K, Chong QY, Zhao J, Liu Y, Shao Y, Zhang Y, Yu Q, Xiong Z, Zhang W, Zhang M, Li G, Li X, Kong X, Ahmad A, Wu Z, Wu Q, Zhao X, Lobie PE, Zhu T.

J Biol Chem. 2017 Aug 18;292(33):13551-13564. doi: 10.1074/jbc.M117.780973. Epub 2017 Jun 21.

13.

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ.

FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19.

14.

Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.

Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R, Hiscox S.

Cancer Biol Ther. 2009 Aug;8(16):1550-8.

PMID:
19830888
15.

The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells.

Yde CW, Clausen MP, Bennetzen MV, Lykkesfeldt AE, Mouritsen OG, Guerra B.

Anticancer Drugs. 2009 Sep;20(8):723-35. doi: 10.1097/CAD.0b013e32832ec041.

PMID:
19584708
16.

Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.

Lykkesfeldt AE.

Acta Oncol. 1996;35 Suppl 5:9-14. Review.

PMID:
9142958
17.

A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.

Rokavec M, Schroth W, Amaral SM, Fritz P, Antoniadou L, Glavac D, Simon W, Schwab M, Eichelbaum M, Brauch H.

Cancer Res. 2008 Dec 1;68(23):9799-808. doi: 10.1158/0008-5472.CAN-08-0247.

18.

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

Osborne CK, Shou J, Massarweh S, Schiff R.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s. Review.

19.

Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells.

Kilker RL, Hartl MW, Rutherford TM, Planas-Silva MD.

J Steroid Biochem Mol Biol. 2004 Sep;92(1-2):63-71.

PMID:
15544931
20.

AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.

Zhao W, Zhang Q, Kang X, Jin S, Lou C.

Biochem Biophys Res Commun. 2009 Mar 13;380(3):699-704. doi: 10.1016/j.bbrc.2009.01.155. Epub 2009 Jan 29.

PMID:
19285025

Supplemental Content

Support Center